A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease - J2A-MC-GZPW

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031250526

Enrollment

7140

Registered

2025-11-27

Start date

2025-12-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis Cardiovascular Disease Chronic Kidney Disease

Interventions

Drug: Orforglipron Administered orally Other Names: - LY3502970 Drug: Placebo Administered orally (Study Arms) Experimental: Orforglipron Participants will receive orforglipron orally + standard of

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Have established ASCVD and/or CKD

Exclusion criteria

Exclusion criteria: - Have type 1 diabetes - Have had a major heart condition within 60 days prior to screening - Have New York Heart Association Functional Classification Class IV heart failure

Design outcomes

Primary

Measure	Time frame
Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events Composite endpoint includes nonfatal myocardial infarction, nonfatal stroke, hospitalization or urgent visit due to heart failure, coronary revascularization, or all-cause death [Time Frame: Baseline up to end of study (about 5 years)]	—

Countries

Canada, Czechia, Germany, Italy, Japan, Mexico, Romania, Spain, United Kingdom

Contacts

Public ContactTrial Guide Call Center

Eli Lilly Japan K.K.

LTG_CallCenter@lists.lilly.com+81-120-023-812

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026